News | February 17, 2025
Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
European operations' revenue grew 58.4% to Rs 599.7 crore
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
Subscribe To Our Newsletter & Stay Updated
